Metsera, Inc. (MTSR) AI Stock Analysis

• Market Cap: $2.51B
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Technology
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 105,050,220
• 10 Day Avg. Volume: 783,622
• 30 Day Avg. Volume: 1,120,513
• PEG Ratio: N/A
• Price to Book (P/B): 8.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -50.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $47.00
• Price Target Upside: 67.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock's potential.

Positive Factors

Financial Stability

Metsera is well-funded with enough cash to last through 2026, providing stability as they advance their clinical trials.

Market Entry

The fully biased, potentially monthly, subQ lead asset, GLP1RA MET-097i, is poised to secure MTSR a stake in the growing obesity market.

Pipeline Development

MTSR's differentiated ultra-long-acting NuSH analog pipeline is seen as a highly promising multi-billion opportunity.

Negative Factors

Clinical Trial Risks

Advancing clinical trials always carries the risk of unforeseen delays or failures, which could impact Metsera's progress.

Market Competition

Metsera's entry into the obesity market might face challenges due to competition from established players.

Metsera, Inc. Business Overview & Revenue Model

Company Description

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

How the Company Makes Money

Metsera, Inc. Financial Statement Overview

Summary

Metsera, Inc. is facing substantial income statement challenges with no revenue and significant losses, which is a major concern for long-term viability. The balance sheet shows strong liquidity due to high cash reserves, but the cash burn rate is a risk factor. While financing activities have bolstered cash position, sustainable revenue generation is crucial for future stability.

Income Statement

Metsera, Inc. shows significant challenges in its income statement, with no reported revenue in both periods. The company has negative EBIT and Net Income, indicating ongoing operational losses without any offsetting revenue. This is a critical weakness for financial stability and growth.

Balance Sheet

The balance sheet of Metsera, Inc. reveals a strong equity position with a significant amount of cash and short-term investments. The debt-to-equity ratio is low due to minimal total debt, and the equity ratio is fairly healthy. However, the company may face risks due to the high net losses impacting equity over time.

Cash Flow

Metsera, Inc. has negative operating and free cash flows, indicating a cash burn situation, which is common in biotech firms in early stages. Despite this, the company shows strong financing cash flow, which could support operations temporarily. However, the cash flow to net income ratios highlight inefficiencies in translating cash flow into profits.

Breakdown
Dec 2024	Dec 2023
Income Statement		Total Revenue
0.00	0.00
	Gross Profit
0.00	0.00
	EBIT
-224.83M	-43.67M
	EBITDA
-218.23M	-47.20M
	Net Income Common Stockholders
-209.13M	-47.21M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
352.45M	75.19M
	Total Assets
450.99M	168.84M
	Total Debt
9.80M	0.00
	Net Debt
-342.64M	-75.19M
	Total Liabilities
163.64M	70.34M
	Stockholders Equity
287.35M	98.50M
Cash Flow		Free Cash Flow
-100.08M	-35.42M
	Operating Cash Flow
-100.04M	-35.39M
	Investing Cash Flow
-43.00K	-28.24M
	Financing Cash Flow
377.95M	123.68M

Metsera, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STNE	65 Neutral	$3.61B	8.73	-8.85%	―	-14.03%	-167.03%
AVPT	65 Neutral	$3.83B	―	-8.39%	―	21.70%	-67.95%
Sector *	60 Neutral	$10.96B	10.27	-6.73%	2.97%	7.73%	-11.60%
POWI	55 Neutral	$2.85B	89.58	4.29%	1.51%	-5.75%	-41.75%
SMTC	53 Neutral	$3.04B	―	-137.83%	―	4.66%	84.78%
AI	53 Neutral	$3.10B	―	-32.07%	―	23.79%	4.10%
MTSR	40 Underperform	$2.51B	―		―	―	―

Metsera, Inc. Corporate Events

Metsera, Inc. Appoints New Board Member and Legal Officer

On April 28, 2025, Metsera, Inc. appointed Jon P. Stonehouse to its Board of Directors as a Class III director, with a term expiring in 2028. Stonehouse, who has a robust background in the pharmaceutical and biotechnology sectors, will also serve on the Audit Committee. His extensive experience includes leadership roles at BioCryst Pharmaceuticals and Merck KgaA, and he is eligible for Metsera’s Non-Employee Director Compensation Program. Additionally, Metsera announced the appointment of Matthew Lang as Chief Legal Officer and Secretary. Lang brings a wealth of legal and executive experience from his previous roles at Lyell Immunopharma and Myovant Sciences, enhancing Metsera’s legal and administrative capabilities.

Spark’s Take on MTSR Stock

According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.

Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.

To see Spark’s full report on MTSR stock, click here.

Metsera, Inc. Approves 2024 Executive Cash Bonuses

On March 7, 2025, Metsera, Inc. announced that its Board of Directors approved the 2024 annual cash bonuses for its named executive officers, based on the company’s performance for the year ended December 31, 2024. The bonuses were set at 100% of each executive’s target annual bonus, and the updated compensation details were provided, reflecting the total compensation for each officer for 2024.